ELEPHAS BIOSCIENCES RAISES $40M TO ACCELERATE COMMERCIALIZATION OF ITS LIVE TUMOR PROFILING PLATFORM

ELEPHAS生物科学公司筹集4000万美元以加速其活体肿瘤分析平台的商业化进程

Reinvestment from existing backers underscores confidence in Elephas' predictive approach to improving immunotherapy treatment response rates

现有支持者的再投资凸显了对Elephas预测方法改善免疫治疗反应率的信心。

MADISON, Wis., November 6, 2025-- Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tumor profiling platform for immunotherapy response prediction, today announced a Series B-2 funding of $40 million.

威斯康星州麦迪逊市，2025年11月6日——Elephas生物科学公司（Elephas），一家开发了创新的活体肿瘤分析平台以预测免疫治疗反应的私人公司，今天宣布完成了4000万美元的B-2轮融资。

The equity round included participation from existing investors including Northpond Ventures, ARCH Venture Partners, the State of Wisconsin Investment Board, Tao Capital Partners, Sands Capital, Venture Investors Health Fund, among others.

本轮融资的现有投资者包括北极星创投、ARCH风险投资公司、威斯康星州投资委员会、涛资本合伙人、桑兹资本、风险投资者健康基金等。

The capital raised will support the launch and commercialization of the proprietary Elephas Live™ Platform as a laboratory developed test (LDT) in 2026. The Elephas Live Platform is designed to functionally profile ex vivo live tumor biopsies. By protecting the native tumor microenvironment and using a novel method to address tumor heterogeneity, the technology allows for prediction of immunotherapy response..

筹集的资金将支持专有的Elephas Live™平台于2026年作为实验室开发测试（LDT）推出和商业化。Elephas Live平台旨在对离体活肿瘤样本进行功能性分析。通过保护天然的肿瘤微环境，并采用一种新方法解决肿瘤异质性问题，该技术能够预测免疫疗法的反应。

'This financing milestone underscores the strong investor confidence in the promise of Elephas and our shared mission to improve the lives of those affected by cancer,' said Maneesh Arora, Elephas founder and CEO. 'We have made incredible progress this year and have strong momentum heading into 2026.

“这一融资里程碑彰显了投资者对Elephas的潜力以及我们改善癌症患者生活的共同使命的强烈信心，”Elephas创始人兼首席执行官Maneesh Arora表示。“今年我们取得了惊人的进展，并且在迈向2026年的过程中保持了强劲的势头。”

This funding achievement will drive our next stage of growth and advance our commercialization strategy.'.

这一融资成果将推动我们下一阶段的增长，并推进我们的商业化战略。

Earlier this fall, Elephas welcomed Jérôme Galon, Ph.D., to the Company's expanding Scientific Advisory Board. Dr. Galon and fellow Elephas advisory board member Janis Taube, M.D., will be joining Elephas at the upcoming Societies for the Immunotherapy in Cancer (SITC) Annual Meeting on November 8, 2025, in National Harbor, MD (link) for a symposium discussing the improved prediction of immunotherapy response..

今年秋天早些时候，Elephas 公司迎来了 Jérôme Galon 博士加入公司不断扩大的科学顾问委员会。Galon 博士和 Elephas 顾问委员会的另一位成员 Janis Taube 医学博士将于 2025 年 11 月 8 日在马里兰州国家港（链接）举行的癌症免疫治疗学会 (SITC) 年会上参与 Elephas 的专题讨论会，探讨如何更好地预测免疫疗法的反应。

XMS Capital Partners acted as financial advisor to the company.

XMS资本合伙人公司担任了该公司的财务顾问。

About Elephas

关于Elephas

Cancer is a leading cause of death worldwide, with the number of patients projected to triple by 2060. Despite a significant increase in the number of available immunotherapies, only 1 in 5 patients receiving immunotherapy obtain a response and many who may respond are not eligible for therapy due to lack of accurate predictive biomarkers.

癌症是全球主要的死亡原因之一，预计到2060年患者数量将增加三倍。尽管可用的免疫疗法数量显著增加，但只有五分之一的患者对免疫疗法有反应，而且许多可能有反应的患者由于缺乏准确的预测性生物标志物而无法接受治疗。

With the mission to tackle this massive dilemma, Elephas has developed an ex-vivo live tumor profiling platform for immunotherapy response prediction. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the Elephas Live platform enables a real-time characterization of immune response.

为了解决这一巨大的难题，Elephas 开发了一种用于免疫治疗反应预测的离体活体肿瘤分析平台。通过从活检针芯样本中保留原始的肿瘤微环境，并采用一种新方法应对肿瘤异质性，Elephas 活体平台实现了对免疫反应的实时特征分析。

To learn more, visit www.elephas.com and search and follow us on LinkedIn..

要了解更多信息，请访问 www.elephas.com 并在 LinkedIn 上搜索并关注我们。